#United States #New York #Class Action #Securities Fraud #Biohaven

Biohaven Ltd. Investors Brace for Legal Action

The Securities and Exchange Commission (SEC) warns investors about potential securities fraud in connection with Biohaven Ltd. (NYSE: BHVN). Rosen Law Firm, a respected law firm that specializes in protecting investors’ rights, has reached out to shareholders who purchased Biohaven's stocks between March 24, 2023, and May 14, 2025. This class period invites eligible investors to consider joining a class action lawsuit against the company. The critical deadline for becoming a lead plaintiff is September 12, 2025.

Investors who bought Biohaven securities during the specified timeframe may be entitled to financial compensation without incurring any out-of-pocket expenses. The Rosen Law Firm emphasizes that individuals can pursue a potential recovery through a contingency fee system, meaning they owe fees only if they achieve a favorable outcome.

How to Get Involved

To participate in this class action, investors can visit Rosen Law Firm's website here or directly contact Phillip Kim, Esq., at (866) 767-3653 or via email at [email protected] for further information. A class action lawsuit has already been initiated, prompting an offer for investors to serve as lead plaintiff. This representative role entails guiding the litigation process for all affected investors.

Why Choose Rosen Law Firm?

The Rosen Law Firm encourages investors to select experienced counsel with a successful track record in leading securities class actions. Often, firms sending notices lack the necessary expertise and reputation to manage complex litigation. Many of these firms serve merely as intermediaries, passing their clients onto other law firms without direct involvement in the cases. Choosing a law firm like Rosen, which focuses on securities class actions and derivative litigation, is crucial. The firm has garnered significant achievements, including the largest settlement against a Chinese company at that time. It ranked number one for multiple years in terms of settlements in securities class action cases and has successfully secured hundreds of millions of dollars for investors over the years. In 2019 alone, the firm achieved a remarkable recovery of over $438 million for its clients.

The Allegations Against Biohaven

The class action lawsuit alleges that during the class period, Biohaven's leadership made misrepresentations about their drug candidates, particularly focusing on their treatment for spinocerebellar ataxia (SCA) and bipolar disorder. It was claimed that Biohaven overstated the regulatory prospects of its drug, troriluzole, and also the efficacy of the BHV-7000 treatment for bipolar disorder. Once this information came to light, it is asserted that it had a negative impact on Biohaven’s market performance and financial stability. As a result, affected investors incurred significant damages.

Next Steps for Investors

Interested parties should investigate these claims carefully to ensure they understand their rights. It is essential to note that although no formal class has been certified at this stage, those who participate in the suit may have the opportunity to recover compensation without having to take on any potential financial risk initially. Investors can also opt to select their counsel or remain uninvolved at this juncture. However, taking action sooner rather than later may enhance their chances of sharing in any future recovery.

Stay connected with the Rosen Law Firm for updates about this litigation through their social media platforms including LinkedIn, Twitter, and Facebook.

Attorney Advertising: Previous outcomes do not guarantee a similar result in future cases.